Critical Contrast: Axe Compute (NASDAQ:AGPU) and CI&T (NYSE:CINT)

CI&T (NYSE:CINT) and Axe Compute (NASDAQ:AGPU) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Earnings and Valuation

This table compares CI&T and Axe Compute”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CI&T	$541.02 million	0.80	$40.62 million	$0.29	11.07
Axe Compute	$120,000.00	750.45	-$233.10 million	($5.75)	-1.35

CI&T has higher revenue and earnings than Axe Compute. Axe Compute is trading at a lower price-to-earnings ratio than CI&T, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.4% of CI&T shares are owned by institutional investors. Comparatively, 9.0% of Axe Compute shares are owned by institutional investors. 1.2% of Axe Compute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

CI&T has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Axe Compute has a beta of 3.66, indicating that its stock price is 266% more volatile than the S&P 500.

Profitability

This table compares CI&T and Axe Compute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CI&T	6.79%	11.69%	6.51%
Axe Compute	-7,769.61%	-1,606.56%	-355.39%

Analyst Ratings

This is a summary of recent ratings and price targets for CI&T and Axe Compute, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CI&T	2	2	7	0	2.45
Axe Compute	1	0	0	1	2.50

CI&T presently has a consensus target price of $6.08, suggesting a potential upside of 89.34%. Given CI&T’s higher possible upside, equities analysts clearly believe CI&T is more favorable than Axe Compute.

Summary

CI&T beats Axe Compute on 10 of the 15 factors compared between the two stocks.

About CI&T

CI&T, Inc. provides strategy, design and software engineering services to enable digital transformation. The firm’s solutions and services include Digital Strategy, Customer-Centric Design and Top-of-the-Line Software Engineering. The company was founded by Cesar Nivaldo Gon, Bruno Guiçardi Neto and Fernando Matt Borges Martins on June 7, 2021 and is headquartered in Sao Paulo, Brazil.

About Axe Compute

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.